natgillin/translations-raw huggingface dataset:
- Behandling af symptomatisk anæmi forbundet med kronisk nyreinsuficiens hos voksne og
4.1 Therapeutic indications
4. 4). − Behandling af anæmi og reduktion af transfusionsbehov hos voksne patienter i kemoterapi for massive tumorer, malignt lymfom eller multipelt myelom og med risiko ved transfusion vurderet ud fra patientens almentilstand (fx kardiovaskulær tilstand, præeksisterende anæmi ved kemoterapistart). − Retacrit kan anvendes til at øge udbyttet af autologt blod fra patienterne i et prædonationsprogram.
− Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: o Treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis (See section 4.4). o Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis (See section 4.4). − Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. g. cardiovascular status, pre-existing anaemia at the start of chemotherapy). − Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme.
Anvendelsen på denne indikation skal afvejes mod den rapporterede risiko for tromboemboli- hændelser.
Its use in this indication must be balanced against the reported risk of thromboembolic events.
Behandlingen bør kun anvendes til patienter med moderat anæmi (ingen jernmangel), hvis blodopbevaringsprocedure ikke er tilgængelig eller er utilstrækkelige, når det planlagte større, kirurgiske operation kræver en stort mængde blod (4 eller flere blodportioner for kvinder og 5 eller flere enheder for mænd). −
Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
4. 4).
Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients In patients with chronic renal failure the medicinal product has to be administered intravenously (see section 4.4)
2 Der tilstræbes en hæmoglobinkoncentration på mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l) undtaget hos pædiatriske patienter, hvis hæmoglobinkoncentration bør ligge mellem 9, 5 og 11 g/ dl (5, 9 - 6, 8 mmol/ l).
2 The haemoglobin concentration aimed for is between 10 and 12 g/ dl (6.2-7.5 mmol/ l), except in paediatric patients in whom the haemoglobin concentration should be between 9.5 and 11 g/ dl (5.9-6.8 mmol/ l).
Det er nødvendigt, at en læge bedømmer den individuelle patients kliniske forløb og tilstand.
Anemia symptoms and sequaelea may vary with age, gender and overall burden of disesase; a physician´s evaluation of the individual patient´s clinical course and condition is necessary.
På grund af variabilitet hos den enkelte patient kan der af og til observeres individuelle hæmoglobinværdier for en patient, som ligger over og under det ønskede hæmoglobinniveau.
Retacrit should be administered intravenously in order to increase haemoglobin to not greater than 12 g/ dL (7.5 mmol/ L) Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed.
Hæmoglobinvariabiliteten bør behandles via dosishåndtering under hensyntagen til det tilstræbte niveau for hæmoglobin på 10 g/ dl (6, 2 mmol/ l) til 12 g/ dl (7, 5 mmol/ l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/ dL (6.2 mmol/ l) to 12 g/ dl (7.5 mmol/ l).
Vejledning for passende dosisjustering, når der er observeret hæmoglobinværdier over 12 g/ dl (7, 5 mmol/ l), er beskrevet nedenfor.
A sustained haemoglobin level of greater than 12 g/ dl should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/ dl (7.5 mmol/ l) are observed are described below.
En stigning i hæmoglobin på mere en 2 g/ dl (1, 25 mmol/ l) over en 4 ugers periode bør undgås.
A rise in haemoglobin of greater than 2 g/ dL (1.25 mmol/ l) over a four week period should be avoided.
Patienterne bør monitoreres nøje for at sikre, at den lavest godkendte dosis af Retacrit anvendes til at sørge for tilstrækkelig kontrol af de anæmiske symptomer.
Patients should be monitored closely to ensure that the lowest approved dose of Retacrit is used to provide adequate control of the symptoms of anemia.
Voksne patienter i hæmodialyse Behandlingen inddeles i to faser:
Adult patients on haemodialysis The treatment is divided into two stages:
Korrektionsfasen:
Correction phase:
50 IU/ kg 3 gange om ugen, intravenøst.
50 IU/ kg 3 times per week by the intravenous route.
For hvert trin bør dosis hhv. øges eller nedsættes med 25 IU/ kg 3 gange om ugen.
At each step, the increase or reduction in dose should be of 25 IU/ kg 3 times per week.
Vedligeholdelses - fasen:
Maintenance phase:
Doseringsjustering for at holde hæmoglobinværdierne (Hb) på det ønskede niveau:
Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level:
Hb mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l).
Hb between 10 and 12 g/ dl (6.2-7.5 mmol/ l).
Den anbefalede totale ugentlige dosis er mellem 75 og 300 IU/ kg, intravenøst.
The recommended total weekly dose is between 75 and 300 IU/ kg by the intravenous route.
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6 g/ dl eller < 3, 75 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med mindre alvorlig initial anæmi (Hb > 8 g/ dl or > 5 mmol/ l).
The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6 g/ dl or< 3.75 mmol/l) may require higher maintenance doses than those whose initial anaemia is less severe (Hb > 8 g/dl or> 5 mmol/l).
Pædiatriske patienter i hæmodialyse Behandlingen inddeles i to faser:
Paediatric patients on haemodialysis The treatment is divided into two stages:
Korrektionsfasen:
Correction phase
50 IU/ kg 3 gange om ugen intravenøst.
50 IU/ kg, 3 times per week by the intravenous route.
Når en regulering af dosis er nødvendig, bør den ske i trin på 25 IU/ kg 3 gange om ugen med intervaller på mindst 4 uger, indtil det ønskede mål er nået.
When a dose adjustment is necessary, this should be done in steps of 25 IU/ kg, 3 times per week at intervals of at least 4 weeks until the desired goal is achieved.
Hb mellem 9, 5 og 11 g/ dl (5, 9- 6, 8 mmol/ l).
Hb between 9.5 and 11 g/ dl (5.9-6.8 mmol/ l).
Vægt (kg) < 10
Dose (IU/ kg given 3x week)
10- 30 > 30
Weight (kg )< 10 10-30 > 30
75 33
Median 100 75 33
60- 150 30- 100
Usual maintenance dose 75-150 60-150 30-100
De tilgængelige kliniske data tyder på, at patienter med meget lavt initialt hæmoglobin (< 6, 8 g/ dl eller < 4, 25 mmol/ l) kan kræve højere vedligeholdelsesdoser end patienter med initialt hæmoglobin på > 6, 8 g/ dl eller > 4, 25 mmol/ l).
3 The clinical data available suggest that those patients whose initial haemoglobin is very low (< 6.8 g/ dl or< 4.25 mmol/l) may require higher maintenance doses than those whose initial haemoglobin is higher > 6.8 g/dl or> 4.25 mmol/l).
Voksne patienter i peritonealdialyse Behandlingen inddeles i to faser:
Adult patients on peritoneal dialysis The treatment is divided into two stages:
Der startes med 50 IU/ kg 2 gange om ugen, intravenøst.
Starting dose of 50 IU/ kg 2 times per week by the intravenous route.
(Hb mellem 10 og 12 g/ dl (6, 2- 7, 5 mmol/ l).
Hb between 10 and 12 g/ dl (6.2-7.5 mmol/ l).
Vedligeholdelsesdosis mellem 25 og 50 IU/ kg 2 gange om ugen i 2 lige store injektioner.
Maintenance dose between 25 and 50 IU/ kg 2 times per week into 2 equal doses.
− Voksne patienter med nyreinsufficiens, der endnu ikke er i dialyse
Adult patients with renal insufficiency not yet undergoing dialysis
Startdosis på 50 IU/ kg 3 gange om ugen, intravenøst, om nødvendigt efterfulgt af en øgning af doseringen med 25 IU/ kg ad gangen (3 gange om ugen), indtil det ønskede mål er nået (dette bør ske i trin på minimum 4 uger).
Starting dose of 50 IU/ kg 3 times per week by the intravenous route, followed if necessary by a dose increase with 25 IU/ kg increments (3 times per week) until the desired goal is achieved (this should be done in steps of at least four weeks).
Doseringsjustering for at bibeholde hæmoglobinværdierne (Hb) på det ønskede niveau:
Dose adjustment in order to maintain haemoglobin (Hb) values at the desired level:
Vedligeholdelsesdosis mellem 17 og 33 IU/ kg 3 gange ugentligt indgivet intravenøst.
Maintenance dose between 17 and 33 IU/ kg 3 times per week by the intravenous route.
Den maksimale dosering bør ikke overstige 200 IU/ kg 3 gange om ugen.
The maximum dose should not exceed 200 IU/ kg 3 times per week.
− Behandling af patienter med kemoterapi- induceret anæmi
− Treatment of patients with chemotherapy induced anaemia..
Retacrit skal indgives subkutant til patienter med anæmi (f. eks. hæmoglobinkoncentration ≤ 10 g/ dl (6, 2 mmol/ l).
Retacrit should be administered by the subcutaneous route to patients with anaemia (e. g. haemoglobin concentration ≤ 10 g/ dl (6.2 mmol/ l).
Hæmoglobinvariabilitet bør håndteres ved at styre dosis, med det tilstræbte hæmoglobininterval på 10 g/ dl (6, 2 mmol/ l) til 12 g/ dl (7, 5 mmol/ l) taget i betragtning.
Haemoglobin variability should be addressed through dose management with consideration for the haemoglobin target range of 10 g/ dl (6.2 mmol/ l) to 12 g/ dl (7.5 mmol/ l).
Der bør fortsættes med Retacrit- terapi indtil 1 måned efter kemoterapiens ophør.
Retacrit therapy should continue until one month after the end of chemotherapy.
Initialdosis er 150 IU/ kg indgivet subkutant 3 gange om ugen.
The initial dose is 150 IU/ kg given subcutaneously 3 times per week.
Alternativt kan Retacrit administreres med en initialdosis på 450 IU/ kg subkutant 1 gang ugentligt.
Alternatively, Retacrit can be administered at an initial dose of 450 IU/ kg subcutaneously once weekly.
Hvis hæmoglobinforøgelsen er < 1 g/ dl
If the haemoglobin has increased by at least 1 g/ dl (0.62 mmol/ l) or the reticulocyte count has increased ≥ 40,000 cells/ µl above baseline after 4 weeks of treatment, the dose should remain at 150 IU/ kg 3 times per week or 450 IU/ kg once weekly.
4 (< 0, 62 mmol/ l), og reticulocyttællingen er steget < 40000 celler/ µl over baseline, øges dosis til 300 IU/ kg 3 gange om ugen.
If the haemoglobin increase is < 1 g/ dl (< 0.62 mmol/ l) and the reticulocyte count has increased < 40,000 cells/ µl above baseline, increase the dose to 300 IU/ kg 3 times per week.
Hvis hæmoglobinet er steget < 1 g/ dl (< 0, 62 mmol/ l), og reticulocyttællingen er steget < 40000 cells/ µl over baseline, er respons dog usandsynlig, og behandling bør ophøre.
If after an additional 4 weeks of therapy at 300 IU/ kg 3 times per week, the haemoglobin has increased ≥ 1 g/ dl (0.62 mmol/ l) or the reticulocyte count has increased ≥ 40,000 cells/ µl the dose should remain at 300 IU/ kg 3 times per week.
Den anbefalede dosis er angivet i følgende diagram:
However, if the haemoglobin
Retikulocyttalsstigning ≥ 40. 000/ mikroliter eller stigning i Hb med ≥ 1 g/ dl
4 has increased < 1 g/ dl (< 0.62 mmol/ l) and the reticulocyte count has increased < 40,000 cells/ µl above baseline, response is unlikely and treatment should be discontinued.
Stigning i retikulocyttal til < 40. 000/ mikroliter og stigning i Hb med < 1 g/ dl
The recommended dosing regimen is described in the following diagram:
Når først behandlingsmålet for den enkelte patient er opnået, bør dosis reduceres med 25- 50% for at fastholde hæmoglobin på det niveau.
Once the therapeutic objective for an individual patient has been achieved, the dose should be reduced by 25 to 50% in order to maintain haemoglobin at that level.
25- 50%.
Dose adjustment At a rate of rise in haemoglobin of > 2 g/ dl (> 1.25 mmol/ l) per month the Retacrit dose should be reduced by about 25-50%.
Hvis hæmoglobinniveauet overstiger 12 g/ dl (7, 5 mmol/ l), ophøres der med terapi, indtil niveauet er faldet til 12 g/ dl (7, 5 mmol/ l) eller derunder, hvorefter Retacrit- terapien genoptages med en dosis, som er 25% under den tidligere dosis.
If haemoglobin level exceeds 12 g/ dl (7.5 mmol/ l), discontinue therapy until it falls to 12 g/ dl (7.5 mmol/ l) or lower and then reinstitute Retacrit therapy at a dose 25% below the previous dose.
− Voksne patienter i et autologt prædonationsprogram
− Adult surgery patients in an autologous predonation programme.
Retacrit bør gives intravenøst.
Retacrit should be given by the intravenous route.
Let anæmiske patienter (hæmatokrit 33- 39%), som kræver en forudgående behandling med ≥ 4 enheder blod, skal behandles med Retacrit med en dosis på 600 IU/ kg legemsvægt 2 gange ugentligt i 3 uger forud for operationen.
Mildly anaemic patients (haematocrit of 33-39%) requiring predeposit of ≥ 4 units of blood should be treated with Retacrit at a dose of 600 IU/ kg body weight 2 times weekly for 3 weeks prior to surgery.
Alle patienter, som behandles med Retacrit, bør have et tilstrækkeligt jerntilskud (fx 200 mg usammensat jern oralt dagligt) under hele behandlingen.
5 All patients being treated with Retacrit should receive adequate iron supplementation (e. g.
Der bør startes med jerntilskud så tidligt som
200 mg oral elemental iron daily) throughout the course of treatment.
6 muligt, gerne flere uger før den autologe prædonation påbegyndes, således, at der opbygges store jerndepoter, før Retacrit- behandling påbegyndes.
Iron supplementation should be started as soon as possible, even several weeks prior to initiating the autologous predeposit, in order to achieve high iron stores prior to starting Retacrit therapy.
a) Intravenøs injektion Dosis skal administreres over mindst 1- 5 minutter, afhængigt af den totale dosis.
Intravenous injection The dose should be administered over at least 1-5 minutes, depending on the total dose.
Alternativt kan der, for at skylle slangen og sikre tilfredsstillende overførsel af produktet til kredsløbet, gives en injektion til sidst i dialysesessionen via fistelnålslangen, efterfulgt af 10 ml natriumkloridopløsning, 9 mg/ ml (0, 9%).
Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 ml of sodium chloride 9 mg/ ml (0.9%) solution for injection to rinse the tubing and ensure satisfactory injection of the medicinal product into the circulation.
En langsommere injektion er at foretrække hos patienter, som reagerer på behandlingen med "influenzalignende" symptomer.
A slower injection is preferable in patients who react to the treatment with “ flu-like” symptoms.
Retacrit bør ikke administreres ved intravenøs infusion.
Retacrit should not be administered by intravenous infusion.
6. 2).
Retacrit must not be mixed with other medicinal products (see section 6.2).
b) Subkutan injektion Et maksimalt volumen på 1 ml på ét injektionssted bør generelt ikke overskrides.
Subcutaneous injection A maximum volume of 1 ml at one injection site should generally not be exceeded.
Til patienter med kronisk nyresvigt må Retacrit ikke gives subkutant.
In chronic renal failure patients Retacrit has not to be administered subcutaneously.
4. 4 – Patienter med kronisk nyreinsufficiens).
The intravenous route has to be used (please see section 4.4 - chronic renal failure patients).
4. 4) − Ukontrolleret hypertension − Ved indikationen ” øgning af udbyttet af autologt blod ”: myokardial infarkt eller slagtilfælde i måneden forud for behandlingen, ustabil angina pectoris, øget risiko for dyb venetrombose, eksempelvis på grund af tromboembolisk venesygdom. − Patienter, som - uanset grund - ikke kan modtage tilstrækkelig antitrombotisk profylakse.
− Hypersensitivity to the active substance or to any of the excipients. − Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin must not receive Retacrit or any other erythropoietin (see section 4.4). − Uncontrolled hypertension. − In the indication "increasing the yield of autologous blood": myocardial infarction or stroke in the month preceding treatment, unstable angina pectoris, increased risk of deep venous thrombosis such as history of venous thromboembolic disease. − Patients who for any reason cannot receive adequate antithrombotic prophylaxis.
Som hos alle patienter, der får erytropoietin, kan blodtrykket stige under behandling med Retacrit.
Like in all patients receiving erythropoietin, blood pressure may rise during treatment with Retacrit.
Hvis blodtrykket ikke kan kontrolleres, skal Retacrit- behandlingen ophøre.
If blood pressure cannot be well controlled, Retacrit treatment should be discontinued.
Der kan optræde en moderat, dosisafhængig stigning i trombocyttallet inden for normalområdet under behandling med erytropoietin.
There may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with erythropoietin.
Alle andre årsager til anæmi (jernmangel, hæmolyse, blodtab, B12- vitamin - eller folatmangel) skal overvejes og behandles forud for påbegyndelse af og under terapi med Retacrit.
6 All other causes of anaemia (iron deficiency, haemolysis, blood loss, vitamin B12- or folate deficiencies) should be considered and treated prior to initiating and during therapy with Retacrit.
For at sikre optimal respons på erytropoietin skal det sikres, at der er tilstrækkelige jerndepoter.
In order to ensure optimum response to erythropoietin, adequate iron stores should be assured: − iron supplementation, e. g.
7 − Jerntilskud, fx 200- 300 mg/ dag peroralt (100- 200 mg/ dag for pædiatriske patienters vedkommende), anbefales til patienter med kronisk nyresvigt, hvis serumferritinniveau er under 100 ng/ ml. − Peroralt jerntilskud på 200- 300 mg/ dag anbefales til alle cancerpatienter, hvis transferrinmætning er under 20%.
200-300 mg/ day orally (100-200 mg/ day for paediatric patients) is recommended for chronic renal failure patients whose serum ferritin levels are below 100 ng/ ml − oral iron substitution of 200-300 mg/ day is recommended for all cancer patients whose transferrin saturation is below 20%.
Alle disse additive faktorer ved anæmi skal også overvejes omhyggeligt, når der træffes beslutning om at øge cancerpatienters erytropoietindosis.
All of these additive factors of anaemia should also be carefully considered when deciding to increase the dose of erythropoietin in cancer patients.
Dette lægemiddel indeholder fenylalanin, som kan være skadeligt for mennesker med fenylketonuri.
This medicinal product contains phenylalanine which may be harmful for people with phenylketonuria.
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. dosis, dvs. det er praktisk taget "natrium- frit".
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i. e. essentially ‘ sodium-free’.
Immunogenicitetsdata for subkutan anvendelse af Retacrit hos patienter med risiko for antistof - fremkaldt Pure Red Cell Aplasia (PRCA), dvs. patienter med renal anæmi, er ikke tilstrækkelige.
Immunogenicity data for subcutaneous use of Retacrit in patients at risk for antibody-induced Pure Red Cell Aplasia (PRCA), i. e. patients with renal anaemia, are not sufficient.
Derfor skal det medicinske produkt gives intravenøst til patienter med renal anæmi.
Therefore, in patients with renal anaemia the medicinal product has to be administered intravenously.
I kliniske forsøg sås en øget risiko for død og alvorlige kardiovaskulære hændelser, når erytropoiesestimulerende stoffer (ESA' er) blev administreret for at tilstræbe et hæmoglobinniveau, som var højere end 12 g/ dl (7, 5 mmol/ l).
In clinical trials, an increased risk of death and serious cardiovascular events was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/ dl (7.5 mmol/ l).
Stigningsraten for hæmoglobin skal være ca.
Haemoglobin levels should be measured on a regular basis until a stable level is achieved and periodically thereafter.
1 g/ dl (0, 62 mmol/ l) pr. måned, og for at minimere risikoen for øget hypertension bør den ikke overstige 2 g/ dl (1, 25 mmol/ l) for at minimere risikoen for, at patienten udvikler eller oplever en forværring af hypertension.
The rate of increase in haemoglobin should be approximately 1 g/ dl (0.62 mmol/ l) per month and should not exceed 2 g/ dl (1.25 mmol/ l) per month to minimize the risk of developing or worsening of hypertension.
Manglende respons på erytropoietin- terapi bør foranledige en søgning efter årsagsfaktorer.
Non response to erythropoietin therapy should prompt a search for causative factors.
Blandt disse er jern -, folat - eller B12- vitaminmangel; aluminiumintoksikation; interkurrente infektioner, inflammatoriske eller traumatiske episoder; okkult blodtab; hæmolyse samt knoglemarvsfibrose af enhver oprindelse.
These include: iron, folate, or Vitamin B12 deficiency; aluminium intoxication; intercurrent infections; inflammatory or traumatic episodes; occult blood loss; haemolysis, and bone marrow fibrosis of any origin.
Tilfælde af erytroblastopeni (PRCA) er rapporteret hos patienter med kronisk nyresvigt, hvor erytropoietin er administreret subkutant.
Cases of antibody-mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route.
Hos patienter, hvor der udvikles pludselig mangel på virkning, defineret som et fald i hæmoglobin (1- 2 g/ dl pr. måned) med øget transfusionsbehov, bør der foretages en reticulocyttælling, og de typiske årsager (fx jern -, folat - eller B12- vitaminmangel, aluminiumsforgiftning, infektion eller inflammation, blodtab og hæmolyse) bør undersøges.
In patients developing sudden lack of efficacy, defined by a decrease in haemoglobin (1-2 g/ dl per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e. g. iron, folate, or Vitamin B12-deficiency, aluminium intoxication, infection or inflammation, blood loss, and haemolysis) should be investigated.
Hvis der diagnosticeres PRCA, skal Retacrit- terapien straks ophøre, og det skal overvejes at teste for antistoffer mod erytropoietin.
If PRCA is diagnosed, therapy with Retacrit must be immediately discontinued and testing for erythropoietin antibodies should be considered.
Patienterne bør ikke overføres til et andet produkt, da anti- erytropoietin - antistoffer krydsreagerer med andre erytropoietiner.
7 product as anti-erythropoietin antibodies cross-react with other erythropoietins.
8 Hyperkalæmi er observeret i isolerede tilfælde.
Hyperkalaemia has been observed in isolated cases.
Ordineringen af dialyse skal måske justeres periodisk for at holde urinstof -, kreatinin - og kalium- niveauerne indenfor det ønskede område.
Dialysis prescriptions may have to be adjusted periodically to maintain urea, creatinine and potassium in the desired range.
Hvis der observeres forhøjet (eller stigende) serum- kaliumniveau, skal det overvejes at ophøre med administrationen af erytropoietin, indtil hyperkalæmien er korrigeret.
If an elevated (or rising) serum potassium level is detected then consideration should be given to ceasing erythropoietin administration until hyperkalaemia has been corrected.
Det er ofte nødvendigt at øge heparindosis under hæmodialyse i forbindelse med erytropoietin- terapi som følge af det øgede erytrocyttal.
An increase in heparin dose during haemodialysis is frequently required during the course of therapy with erythropoietin as a result of the increased packed cell volume.